Retatrutide, from Soma Chems , is receiving significant attention as a novel therapy for obesity control . This dual-action drug merges the activity of a GLP-1 receptor agonist and a GIP receptor activator , aiming to simply promote reduced body fat but also address related metabolic conditions . Preliminary human data have shown promising efficacy